Avid Bioservices Announces Launch of Analytical and Process Development Suites Within New, World-Class Viral Vector Development and Manufacturing Facility

AD/PD Laboratories Open Exactly Eight Months After Announced Plans to Build Viral Vector Facility Build-Out of Facility’s CGMP Manufacturing Suites...

Vyluma and Laboratoires Théa Enter into Licensing Agreement for the Registration and Commercialization of NVK002 in Canada, Mexico, and Select South American Countries

BRIDGEWATER, N.J., June 14, 2022 (GLOBE NEWSWIRE) -- Vyluma, Inc. (“Vyluma”), a biopharmaceutical company developing multiple assets in the ophthalmic...

error: Content is protected !!